Protagonist Therapeutics, Inc
$143.00
-$0.70 (-0.49%)
$140.44Day Range$144.58
Key Statistics
Market Cap
$9.25B
Shares Outstanding
64.7M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Aug 11, 2016
Round Lot
100
Locale
US
Trading Data
Day Open
$143.09
Day High
$144.58
Day Low
$140.44
Volume
1.84M
VWAP
$143.07
Prev Close
$143.70
Transactions
--
Acc. Volume
--
About Protagonist Therapeutics, Inc
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.
PHARMACEUTICAL PREPARATIONSSIC 2834141 employees7707 GATEWAY BLVD., SUITE 140, NEWARK, CA, 94560-1160(510) 474-0170IPO Aug 11, 2016US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001377121
- Composite FIGI
- BBG002B63KM7
- Share Class FIGI
- BBG002B63KP4
- Ticker Root
- PTGX
- SIC Code
- 2834
About Protagonist Therapeutics, Inc (PTGX) Stock
Protagonist Therapeutics, Inc (PTGX) closed the 2026-09-18 session at $143.00, down 0.49% versus the previous close (-0.70). The stock opened at $143.09 and traded between $140.44 and $144.58 during that session. Session trading volume was 1.8M shares. The volume-weighted average price (VWAP) is $143.07.
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.
Protagonist Therapeutics, Inc has a market capitalization of $9.25 billion. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. PTGX is listed on the XNAS exchange. The company employs approximately 141 people. Protagonist Therapeutics, Inc is headquartered in NEWARK, CA. The recorded listing date is 2016-08-11.
On this page you can find market PTGX stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.